Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference
August 03, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and...
Albireo to Report Second Quarter 2021 Financial Results on August 5
July 29, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, July 29, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a...
MULTIMEDIA UPDATE - Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
July 20, 2021 17:21 ET
|
Albireo Pharma, Inc.
– Only once-daily drug indicated for the treatment of pruritus in PFIC – – Commercial launch of Bylvay immediate; available for prescription in the coming days – – Rare Pediatric Disease Priority...
Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
July 20, 2021 16:00 ET
|
Albireo Pharma, Inc.
– Only once-daily drug indicated for the treatment of pruritus in PFIC – – Commercial launch of Bylvay immediate; available for prescription in the coming days – – Rare Pediatric Disease Priority...
Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (PFIC)
July 19, 2021 08:01 ET
|
Albireo Pharma, Inc.
– First approval in the world of Bylvay for the treatment of PFIC – – Only once-daily drug indicated to treat all forms of PFIC – – European Commission (EC) decision based on data from the largest...
Albireo to Present at the William Blair Biotech Focus Conference 2021
July 08, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and...
Albireo to Present at Piper Sandler’s Virtual EASL Takeaway Day
June 24, 2021 08:00 ET
|
Albireo Pharma, Inc.
BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and...
Albireo Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming EASL International Liver Congress
June 21, 2021 06:00 ET
|
Albireo Pharma, Inc.
– Bylvay demonstrates rapid reductions in serum bile acids and long-term improvements in growth, sleep, and hepatic parameters – – Bylvay patient responder data show sustained improvements in...
Albireo to Showcase New Data at the EASL International Liver Congress™ 2021
June 10, 2021 08:30 ET
|
Albireo Pharma, Inc.
– Phase 3 data presentations on long-term treatment and substantial clinical benefits of Bylvay™ (odevixibat) – – Data presentations on Phase 1 product candidate, A3907, in development for adult...
New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerability, and Treatment Benefits of Bylvay™ (odevixibat) in PFIC
June 03, 2021 16:30 ET
|
Albireo Pharma, Inc.
– Data being presented show long-term benefits of Bylvay in children with PFIC – – First potential non-invasive treatment option that could transform the treatment paradigm – – Observed long-term...